Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library

Bioorganic & Medicinal Chemistry Letters
2000.0

Abstract

An efficient combination solution-phase/solid-phase route enabling the diversification of the P1', P2', and P3 subsites of indinavir has been established. The synthetic sequence can facilitate the rapid generation of HIV protease inhibitors possessing more favorable pharmacokinetic properties as well as enhanced potencies. Multiple compound dosing in vivo may also accelerate the identification of potential drug candidates.

Knowledge Graph

Similar Paper

Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library
Bioorganic & Medicinal Chemistry Letters 2000.0
A Combinatorial Library of Indinavir Analogues and Its In Vitro and In Vivo Studies
Bioorganic & Medicinal Chemistry Letters 2002.0
Novel HIV-1 protease inhibitors active against multiple PI-Resistant viral strains: coadministration with indinavir
Bioorganic & Medicinal Chemistry Letters 2003.0
Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus
Bioorganic & Medicinal Chemistry Letters 2007.0
The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains
Bioorganic & Medicinal Chemistry Letters 2003.0
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent
Bioorganic & Medicinal Chemistry Letters 2003.0
Novel inhibitors of HIV protease
Bioorganic & Medicinal Chemistry Letters 2000.0
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains
Bioorganic & Medicinal Chemistry Letters 2002.0
HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1′ substituent
Bioorganic & Medicinal Chemistry Letters 2003.0
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-Resistant viral strains
Bioorganic & Medicinal Chemistry Letters 2002.0